These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31081381)

  • 21. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls.
    Bianco P; Barker R; Brüstle O; Cattaneo E; Clevers H; Daley GQ; De Luca M; Goldstein L; Lindvall O; Mummery C; Robey PG; Sattler de Sousa E Brito C; Smith A
    EMBO J; 2013 May; 32(11):1489-95. PubMed ID: 23644381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic journeys: the hopeful travails of stem cell tourists.
    Petersen A; Seear K; Munsie M
    Sociol Health Illn; 2014 Jun; 36(5):670-85. PubMed ID: 24266861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The emergence and popularisation of autologous somatic cellular therapies in Australia: therapeutic innovation or regulatory failure?
    McLean AK; Stewart C; Kerridge I
    J Law Med; 2014 Sep; 22(1):65-89. PubMed ID: 25341320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Untested Stem Cell Treatments: An Analysis of Australia's Current Regulatory Regime.
    Cavasinni N; Foong P
    J Law Med; 2024 May; 31(1):105-121. PubMed ID: 38761392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stem Cell Treatments in India: An Ethnography of Regular Practice.
    Kandhari R
    Med Anthropol; 2021; 40(4):348-360. PubMed ID: 33427512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
    Bauer G; Elsallab M; Abou-El-Enein M
    Stem Cells Transl Med; 2018 Sep; 7(9):676-685. PubMed ID: 30063299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stem cell tourism--a web-based analysis of clinical services available to international travellers.
    Connolly R; O'Brien T; Flaherty G
    Travel Med Infect Dis; 2014; 12(6 Pt B):695-701. PubMed ID: 25449045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What's missing? Discussing stem cell translational research in educational information on stem cell "tourism".
    Master Z; Zarzeczny A; Rachul C; Caulfield T
    J Law Med Ethics; 2013; 41(1):254-68. PubMed ID: 23581669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments.
    Tanner C; Munsie M; Sipp D; Turner L; Wheatland C
    Health (London); 2019 Jul; 23(4):436-457. PubMed ID: 30782021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. International stem cell tourism and the need for effective regulation. Part II: Developing sound oversight measures and effective patient support.
    Cohen CB; Cohen PJ
    Kennedy Inst Ethics J; 2010 Sep; 20(3):207-30. PubMed ID: 21133333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Between the Local and the Global:
    Hauskeller C
    Perspect Biol Med; 2018; 61(1):42-58. PubMed ID: 29805147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic Mesenchymal Stem Cell-Based Treatment Legislation in Latin America: The Need for Standardization in a Medical Tourism Context.
    Orozco-Solares TE; León-Moreno LC; Rojas-Rizo A; Manguart-Páez K; Caplan AI
    Stem Cells Dev; 2022 Apr; 31(7-8):143-162. PubMed ID: 35216516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.
    Lysaght T; Kerridge IH; Sipp D; Porter G; Capps BJ
    J Bioeth Inq; 2017 Jun; 14(2):261-273. PubMed ID: 28247202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
    Horner C; Tenenbaum E; Sipp D; Master Z
    NPJ Regen Med; 2018; 3():5. PubMed ID: 29479481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stem cell treatments in China: rethinking the patient role in the global bio-economy.
    Chen H; Gottweis H
    Bioethics; 2013 May; 27(4):194-207. PubMed ID: 22092539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking the rise of stem cell tourism.
    Ryan KA; Sanders AN; Wang DD; Levine AD
    Regen Med; 2010 Jan; 5(1):27-33. PubMed ID: 20017692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.